Registered entities
Immunitas Therapeutics, Inc.
Reg. No. 84-2813217United States
Innovation
4 patent families (1 granted) — focus: Chemistry & metallurgy, Physics & computing; filing pace accelerating. Cited 274 times.
| Year | Filings |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 4 |
Social engagement
Social engagement: 9.1K social following, 5 posts in the last 12 months — below the industry typical range.
Investor mix
17 investors on record; lead investors include Agent Capital, Novartis Venture Fund, Leaps by Bayer.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 10 | 59% |
| Private equity | 1 | 6% |
| Other / undisclosed | 6 | 35% |
Recent activity
12 May 2026
Partnership
Boehringer Ingelheim
17 Mar 2026
Event
American Association for Cancer Research 2026 Annual Meeting
12 Nov 2025
Event
panel with other biotech CEOs and academic founders on getting from discovery to the clinic in oncology